Sol-Gel Technologies Ltd.
No enriched coverage for $SLGL in the last 7 days.
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
Opaleye Management Inc. purchased 1,695 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.64 ($73.43–$73.89, $0.12M total) across 2 trades over 2026-07-13 to 2026-07-14.
Opaleye Management Inc. purchased 529 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.80 ($73.69–$73.95) across 2 trades over 2026-07-08 to 2026-07-10.
Recent SLGL coverage spans insider activity, financial news and market movers.
In the last 30 days, SLGL insiders filed 3 SEC Form 4 transactions — 3 purchases ($142K) and no sales. The most active reporter was Opaleye Management Inc. with 3 filings.
A defined Phase 3 topline window helps traders map catalysts and manage event risk.
This is an insider/affiliate open-market purchase with no 10b5-1 plan, but it is small relative to typical institutional flows.
This is a routine insider Form 4 purchase with modest size and no 10b5-1 plan, but it is unlikely to drive near-term price by itself.
The filing signals continued insider/owner accumulation, but it is not a fundamental catalyst like earnings, guidance, or a deal.
The significant stake suggests potential for increased shareholder support or influence, possibly leading to upward price movement.
alphai scores every news story that mentions SLGL with an AI model for sentiment and relevance, and aggregates insider trades from Sol-Gel Technologies Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readOpaleye Management Inc. purchased 1,695 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.64 ($73.43–$73.89, $0.12M total) across 2 trades over 2026-07-13 to 2026-07-14.
2 min readOpaleye Management Inc. purchased 529 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.80 ($73.69–$73.95) across 2 trades over 2026-07-08 to 2026-07-10.
2 min readOpaleye Management Inc. purchased 1,712 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $71.97 ($71.97–$71.99, $0.12M total) across 2 trades over 2026-07-01 to 2026-07-02.
3 min readGreat Point Partners, LLC, Dr. Jeffrey R. Jay, and Ms. Lillian Nordahl have disclosed an 8.45% beneficial ownership stake in Sol-Gel Technologies Ltd. (SLGL). This stake, totaling 274,363 ordinary shares, is reported in a Schedule 13G filing. The percentage is based on 3,245,270 shares outstanding as of March 24, 2026, and the reporting persons share voting and dispositive power over these shares, which are held by funds managed by Great Point.
3 min read• Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed.
3 min readNESS ZIONA, Israel, May 23, 2025 ( GLOBE NEWSWIRE ) -- Sol-Gel Technologies, Ltd. ( NASDAQ: SLGL ) , a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025
2 min read
